Roche launches CE-marked VENTANA MMR IHC Panel
Roche announced the launch of the CE-marked VENTANA MMR IHC Panel, which provides clinicians with a comprehensive group of immunohistochemistry tests for patients diagnosed with colorectal cancer. The tests detect certain proteins associated with a DNA repair mechanism called mismatch repair, and aid in differentiating between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer. About 3% of colorectal cancers are associated with Lynch syndrome. "This testing impacts not just the patient, but family members who may benefit from further genetic testing and advanced monitoring to detect colorectal cancer at its earlier stages, when it is more treatable," said Ann Costello, Head of Roche Tissue Diagnostics. "The VENTANA MMR IHC Panel provides clinicians with an additional tool to perform universal tumor screening for probable Lynch syndrome as recommended by medical guidelines."